EP0711168A4 - METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS - Google Patents

METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS

Info

Publication number
EP0711168A4
EP0711168A4 EP94922680A EP94922680A EP0711168A4 EP 0711168 A4 EP0711168 A4 EP 0711168A4 EP 94922680 A EP94922680 A EP 94922680A EP 94922680 A EP94922680 A EP 94922680A EP 0711168 A4 EP0711168 A4 EP 0711168A4
Authority
EP
European Patent Office
Prior art keywords
methods
associated conditions
treating apoptosis
apoptosis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94922680A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0711168A1 (en
Inventor
L David Tomei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LXR Biotechnology Inc
Original Assignee
LXR Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LXR Biotechnology Inc filed Critical LXR Biotechnology Inc
Publication of EP0711168A1 publication Critical patent/EP0711168A1/en
Publication of EP0711168A4 publication Critical patent/EP0711168A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94922680A 1993-07-23 1994-07-22 METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS Withdrawn EP0711168A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9678893A 1993-07-23 1993-07-23
US96788 1993-07-23
PCT/US1994/008268 WO1995003054A1 (en) 1993-07-23 1994-07-22 Methods of treating apoptosis and associated conditions

Publications (2)

Publication Number Publication Date
EP0711168A1 EP0711168A1 (en) 1996-05-15
EP0711168A4 true EP0711168A4 (en) 1998-04-01

Family

ID=22259083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94922680A Withdrawn EP0711168A4 (en) 1993-07-23 1994-07-22 METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS

Country Status (7)

Country Link
EP (1) EP0711168A4 (pt)
JP (1) JPH09503749A (pt)
KR (1) KR960703597A (pt)
AU (1) AU7370594A (pt)
BR (1) BR9407145A (pt)
CA (1) CA2167805A1 (pt)
WO (1) WO1995003054A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3866800B2 (ja) * 1996-08-29 2007-01-10 東菱薬品工業株式会社 アポトーシス関連疾患の予防及び／又は治療薬
HUP0202791A3 (en) * 1999-09-10 2003-02-28 Cyathus Exquirere Pharmaforsch Pharmaceutical compositions for treating psoriasis
US6693100B1 (en) 1999-09-10 2004-02-17 Iervant Zarmanian Pharmaceutical compositions for treating psoriasis
AU5150200A (en) * 1999-11-24 2001-06-04 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
US6552025B1 (en) 1999-11-24 2003-04-22 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
EP2517721A3 (en) * 2003-05-15 2013-04-10 DMI Biosciences, Inc. Treatment of T-cell mediated diseases
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
MX2014003856A (es) 2011-10-10 2015-01-16 Ampio Pharmaceuticals Inc Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos.
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR20170045274A (ko) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 관절 징후의 치료
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008460A1 (en) * 1990-11-15 1992-05-29 Windleshaw Enterprises Limited Bis-dioxopiperazines for treating liver tumours

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916072D0 (en) * 1989-07-13 1989-08-31 Creighton Andrew M Pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008460A1 (en) * 1990-11-15 1992-05-29 Windleshaw Enterprises Limited Bis-dioxopiperazines for treating liver tumours

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BU'LOCK ET AL.: "Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease", BRITISH HEART JOURNAL, vol. 70, no. 2, 1993, pages 185 - 188, XP002046920 *
CHACHOUA ET AL.: "Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS)", INVEST. NEW DRUGS, vol. 7, no. 4, 1989, pages 327 - 332, XP002046916 *
DUKE ET AL.: "Immunosuppression by the Bisdioxopiperazines ICRF 154 and 159", BIOMEDICINE, vol. 18, no. 3, 1973, pages 199 - 205, XP002046918 *
HAUG ET AL.: "Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, razoxane and interferon.", CELL PROLIFERATION, vol. 26, no. 3, - 1993, pages 251 - 261, XP002046919 *
HELLMAN K.: "Effect of ICRF 159 on Immune Responses.", PROC. ROY. SOC. MED., vol. 65, no. 3, 1972, pages 264 - 265, XP002046917 *
HERMAN ET AL.: "Protective Effect of ICRF-187 on Doxorubicin-Induced Cardiac and Renal Toxicity in Spontaneously Hypertensive (SHR) and Normotensive (WKY) Rats", TOXICOL. APPL. PHARMACOL., vol. 92, no. 1, 1988, pages 42 - 53, XP002046921 *
HERMAN ET AL.: "Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.", CANCER CHEMOTHER. PHARMACOL., vol. 32, no. 6, 1993, pages 445 - 449, XP002046922 *
HERMANN ET AL.: "Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy", CANCER TREAT. REVIEWS, vol. 17, no. 2-3, 1990, pages 155 - 160, XP002046923 *
ONISHI ET AL.: "BIS(2,6-DIOXOPIPERAXINE) DERIVATIVES, TOPOISOMERASE ii INHIBITORS WHICH DO NOT FORM A DNA CLEAVABLE COMPLEX, INDUCE THYMOCYTE APOPTOSIS", BIOCHEM. MOL. BIOL. INT., vol. 32, no. 1, 1994, pages 115 - 122, XP002046924 *
See also references of WO9503054A1 *
SEHESTED ET AL.: "ANTAGONISTIC EFFECT OF THE CARDIOPROTECTOR (+)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187) ON DNA BREAKS AND CYTOTOXICITY INDUCED BY THE TOPOISOMERASE II DIRECTED DRUGS DAUNORUBICIN AND ETOPOSIDE (VP-16)", BIOCHEMICAL PHARMACOL., vol. 46, no. 3, 1993, pages 389 - 393, XP002046915 *
TANABE ET AL.: "Inhibition of Topoisomerase II by Antitumor Agents Bis(2,6-dioxopiperazine) Derivatives", CANCER RESEARCH, vol. 51, 1991, pages 4903 - 4908, XP002046914 *

Also Published As

Publication number Publication date
KR960703597A (ko) 1996-08-31
BR9407145A (pt) 1996-09-17
CA2167805A1 (en) 1995-02-02
WO1995003054A1 (en) 1995-02-02
JPH09503749A (ja) 1997-04-15
AU7370594A (en) 1995-02-20
EP0711168A1 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
ZA965088B (en) Methods of preventing or treating allergles
ZA945426B (en) Treatment of tachyarrhytmias of supraventricular origin
EP0711168A4 (en) METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS
EP0586687A4 (en) Trans-sialidase and methods of use and making thereof
GB9324773D0 (en) Treatment of cellulose
ZA94338B (en) Treatment of waste petroleum
HU9402361D0 (en) New makrolides and use of them
PL301204A1 (en) Method of obtaining avermectines and invermectines
GB9218027D0 (en) Novel method of treatment
GB9202196D0 (en) Method of treatment
EP0454169A3 (en) Photomask and method of treating the same
ZA936166B (en) Methods of treating cancer
GB9317943D0 (en) Treatment of laminitis
GB9321679D0 (en) Treatment of substrates
GB9201391D0 (en) Method of treatment
EP0696055A3 (en) Electronic assemblies and processing methods
GB2265366B (en) Treatment of waste
AU1033295A (en) Methods of physical water treatment and apparatus therefor
EP0752856A4 (en) METHOD FOR TREATING HYPERLIPIDEMIA
GB9408916D0 (en) Treatment of sewage
EP0705104A4 (en) ANTI-CANCER THERAPY
GB9211484D0 (en) Apparatus and method for the treatment of effluent
GB9314466D0 (en) Methods of treating diamonds
GB9317989D0 (en) Treatment of laminitis
GB9502689D0 (en) Prevention and treatment of dementia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980426